Based on the BeyondSpring Inc stock (BYSI stock price) forecasts from 3 analysts, the average analyst target price for BeyondSpring Inc (BYSI stock price) is $11.66 over the next 12 months. BeyondSpring Inc’s (BYSI stock price) average analyst rating is . Stock Target Advisor’s own stock analysis of BeyondSpring Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, BeyondSpring Inc’s stock price was USD 1.54. BeyondSpring Inc’s stock price has changed by +0.16% over the past week, +0.25% over the past month and -86.20% over the last year.
Together with its subsidiaries, BeyondSpring Inc., a biopharmaceutical business in the clinical stages, focuses on the creation of cancer treatments. The Plinabulin, a selective immune-modulating microtubule-binding agent, is the company’s main asset. It has successfully completed Phase III clinical studies for the treatment of advanced non-small cell lung cancer as well as the prevention of chemotherapy-induced neutropenia. Additionally, it is combining Plinabulin with a variety of immuno-oncology drugs, such as nivolumab, a PD-1 antibody for the treatment of NSCLC, nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC, and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of different cancers. The company also works on a medication development platform and three small molecule immune medicines that are in the preclinical phases of development. The business was established in 2010 and has its corporate headquarters in New York.
What we like:
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What we don’t like:
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector